Biotinylated Human VEGF165 Protein, His,Avitag™ (HPLC verified)

Customer Reviews
Cat. No. / Size
Price
Qty
VE5-H82Q0-25ug
$300.00
VE5-H82Q0-200ug
$1110.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

  • Source

    Biotinylated Human VEGF165, His,Avitag (VE5-H82Q0) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4). In the region Ala 27 - Arg 191, the amino acid sequences of VEGF165 from Human, Cynomolgus and Rhesus macaque are identical.

    Predicted N-terminus: His

    Request for sequence

  • Molecular Characterization

    VEGF165 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 22.4 kDa (monomer). The protein migrates as 23-28 kDa (monomer) under reducing (R) condition, and 40-55 kDa (homodimer) when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-HPLC.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    VEGF165 SDS-PAGE

    Biotinylated Human VEGF165, His,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-HPLC

    VEGF165 SEC-HPLC

    The purity of Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     VEGF165 ELISA

    Immobilized Human VEGF R2, His Tag (Cat. No. KDR-H5227) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a linear range of 2-39 ng/mL (QC tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Anti-VEGF MAb, Human IgG1 (Avastin) at 5 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a linear range of 1-15.6 ng/mL (Routinely tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Human VEGF R2, His Tag (Cat. No. KDR-H5227) at 2 μg/mL (100 μL/well), can bind pre-mixed increasing concentrations of Bevacizumab and 0.05 μg/mL (100 μL/well) Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a half maximal inhibitory concentration (IC50) of 0.74 μg/mL (Routinely tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Human VEGF R1 Protein, Fc Tag (Cat. No. VE1-H5253) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a linear range of 0.02-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-TR-FRET

     VEGF165 TR-FRET

    In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-Human IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA02) is used as the Acceptor. Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0), at 0.3 ng/well, can bind to the Ivonescimab with a linear detection range of 16-0.001 μg/mL (Routinely tested).

  • Bioactivity-SPR

     VEGF165 SPR

    Immobilized Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on CM5 Chip via Streptavidin, can bind Avastin with an affinity constant of 0.417 nM as determined in SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     VEGF165 BLI

    Loaded Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on SA Biosensor, can bind Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) with an affinity constant of 21.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  VEGF165 BLI

    Loaded Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on SA Biosensor, can bind Human VEGF R1, His Tag with an affinity constant of 3.36 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Recent Advances

 
Drug Development Progress
  • English Name:

    Vascular endothelial growth factor A

  • Category:

  • Approved Drugs:

    54 Details

  • Drugs in Clinical Trials:

    61 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland